Live Breaking News & Updates on Canntab Therapeutics Inc

Stay updated with breaking news from Canntab therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Canntab Therapeutics Limited: Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.


Canntab Therapeutics Limited: Canntab Fulfills 80% of Its Contract with MediPharm Labs Corp.
Company or
Canntab ), the leading innovator in cannabinoid and terpene blends in hard pill form for medical and therapeutic applications, is pleased to announce that it has completed its 2
nd (second) delivery of (2) (two) additional SKU s ordered by MediPharm Labs Corp ( MediPharm Labs ) (TSX: LABS) (OTCQX: MEDIF) including 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately $550,000.00. Canntab has now fulfilled 80% of the purchase amount contracted under the wholesale table purchase agreement entered into by the Company and MediPharm Labs in June, 2020. ....

United States , Frank Candido , Larry Latowsky , Canntab Therapeutics Inc , Company Or Canntab , Canntab Therapeutics Limited , Canntab Therapeutics Limited Larry Latowsky , Canntab Therapeutics Limited Richard Goldstein , Cannabis Research Licence , Neither The Canadian Securities Exchange , Clinical Research Organization , Medipharm Labs Corp , Canadian Securities Exchange , Frankfurt Stock Exchange , Newsfile Corp , Investor Relations Canntab Therapeutics , Health Canada , Business Development , Therapeutics Limited , Medipharm Labs , Chief Executive Officer , Canntab Therapeutics , Canadian Licensed Producer , Cannabis Standard Processing , Medical Purposes Licence , Industrial Hemp Licence ,

Canntab Therapeutics Limited: Canntab Announces Closing of Convertible Debenture Private Placement


Canntab Therapeutics Limited: Canntab Announces Closing of Convertible Debenture Private Placement
Canntab Therapeutics Limited.
(CSE: PILL) (OTCQB: CTABF) (FSE: TBF1)
( Canntab or the Company ), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the closing of a non-brokered private placement (the
Offering ) of secured convertible debentures of the Company (
Convertible Debentures ), pursuant to which the Company issued Convertible Debentures for gross proceeds of $1,575,000 (the
Convertible Debentures ). The proceeds will be used to fund working capital for the Company, and for general corporate purposes.
The Convertible Debentures are convertible into common shares of the Company (each, a ....

United States , Richard Goldstein , Larry Lotowsky , Larry Latowsky , Company Convertible Debentures , Canntab Therapeutics Inc , Company Stock Option Plan , Canntab Therapeutics , Cannabis Research Licence , Frankfurt Stock Exchange , Newsfile Corp , Us Newswire Services , Neither The Canadian Securities Exchange , Health Canada , Canadian Securities Exchange , Convertible Debentures , Conversion Price , Closing Date , Maturity Date , Convertible Debenture , Exercise Price , Stock Option Plan , Multilateral Instrument , Minority Security Holders , Special Transactions , Chief Financial Officer ,